MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Neamati, N.
Right arrow Articles by Pommier, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Neamati, N.
Right arrow Articles by Pommier, Y.

Vol. 52, Issue 6, 1041-1055, 1997

Potent Inhibitors of Human Immunodeficiency Virus Type 1 Integrase: Identification of a Novel Four-Point Pharmacophore and Tetracyclines as Novel Inhibitors

Nouri Neamati, Huixiao Hong, Sanjay Sunder, George W. A. Milne, and Yves Pommier

Laboratories of Molecular Pharmacology (N.N., S.S., Y.P.) and Medicinal Chemistry (H.H., G.W.A.M.), Division of Basic Sciences, National Cancer Institute, Bethesda, Maryland 20892

A four-point pharmacophore was constructed from energy-minimized structures of chicoric acid and dicaffeoylquinic acid. The search of 206,876 structures in the National Cancer Institute 3D database yielded 179 compounds that contain this pharmacophore. Thirty-nine of these compounds were tested in an in vitro assay specific for human immunodeficiency virus type 1 integrase (IN). Each retrieved structure was fit to the pharmacophore, and the conformation that afforded the best fit was identified. Twenty of the 39 compounds tested exhibited IC50 values of <20 µM. Among the most potent inhibitors, tetracyclines emerged as a new class of inhibitors. Although the parent tetracycline exhibited marginal potency against purified IN, all substituted tetracyclines tested showed 5-100-fold increased potency. Disintegration assays with truncated IN mutants indicated that tetracyclines inhibit the IN catalytic core domain. To investigate whether chelation of divalent metals is implicated in differential potency of tetracyclines, enzyme assays were performed in the presence of both Mn2+ or Mg2+; no significance difference in potency was observed. Rolitetracycline inhibited IN/DNA complex formation in the presence of EDTA, which suggests that inhibition was metal independent. Rolitetracycline reversed DNA binding of IN after the complex was allowed to form before the addition of drug. Selectivity of tetracyclines was also examined in an assay specific for topoisomerase I, and none of the tetracyclines tested induced topoisomerase I-mediated cleavable complex or inhibited camptothecin-induced cleavable complex. Remarkable potency against the IN in the absence of divalent metals and the core enzyme coupled with water solubility makes tetracyclines potential candidates for X-ray crystal structure determination with IN.

Copyright © 1997 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
E. A. Semenova, A. A. Johnson, C. Marchand, D. A. Davis, R. Yarchoan, and Y. Pommier
Preferential Inhibition of the Magnesium-Dependent Strand Transfer Reaction of HIV-1 Integrase by {alpha}-Hydroxytropolones
Mol. Pharmacol., April 1, 2006; 69(4): 1454 - 1460.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. A. Johnson, W. Santos, G. C. G. Pais, C. Marchand, R. Amin, T. R. Burke Jr., G. Verdine, and Y. Pommier
Integration Requires a Specific Interaction of the Donor DNA Terminal 5'-Cytosine with Glutamine 148 of the HIV-1 Integrase Flexible Loop
J. Biol. Chem., January 6, 2006; 281(1): 461 - 467.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
S. John, T. M. Fletcher III, and C. B. Jonsson
Development and Application of a High-Throughput Screening Assay for HIV-1 Integrase Enzyme Activities
J Biomol Screen, September 1, 2005; 10(6): 606 - 614.
[Abstract] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C. Plasencia, R. Dayam, Q. Wang, J. Pinski, T. R. Burke Jr., D. I. Quinn, and N. Neamati
Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell lines
Mol. Cancer Ther., July 1, 2005; 4(7): 1105 - 1113.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
R. B. Turner
Echinacea for the Common Cold: Can Alternative Medicine Be Evidence-Based Medicine?
Ann Intern Med, December 17, 2002; 137(12): 1001 - 1002.
[Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
R. B. Turner, D. K. Riker, and J. D. Gangemi
Ineffectiveness of Echinacea for Prevention of Experimental Rhinovirus Colds
Antimicrob. Agents Chemother., June 1, 2000; 44(6): 1708 - 1709.
[Abstract] [Full Text]

Home page
 J. Virol.Home page
K. Zhu, M. L. Cordeiro, J. Atienza, W. E. Robinson Jr., and S. A. Chow
Irreversible Inhibition of Human Immunodeficiency Virus Type 1 Integrase by Dicaffeoylquinic Acids
J. Virol., April 1, 1999; 73(4): 3309 - 3316.
[Abstract] [Full Text]

Home page
 J. Virol.Home page
P. J. King and W. E. Robinson Jr.
Resistance to the Anti-Human Immunodeficiency Virus Type 1 Compound L-Chicoric Acid Results from a Single Mutation at Amino Acid 140 of Integrase
J. Virol., October 1, 1998; 72(10): 8420 - 8424.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
N. Neamati, A. Mazumder, S. Sunder, J. M. Owen, M. Tandon, J. W. Lown, and Y. Pommier
Highly Potent Synthetic Polyamides, Bisdistamycins, and Lexitropsins as Inhibitors of Human Immunodeficiency Virus Type 1 Integrase
Mol. Pharmacol., August 1, 1998; 54(2): 280 - 290.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics